• Lonza nominated Pearl Huang as an independent board member, pending election at the May 2027 AGM.
• Huang would join the Strategy and Innovation Committee, plus the Remuneration Committee.
• She is an independent director at Waters Corp. and BB Biotech; previously held senior roles at Roche, GSK, Merck.
• Angelica Kohlmann, chair of the Strategy and Innovation Committee, will not stand for re-election at the 2027 AGM.
• Christoph Mäder, lead independent director and chair of the Remuneration Committee, will not stand for re-election at the 2027 AGM.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lonza Group Ltd. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2407386_en) on September 30, 2026, and is solely responsible for the information contained therein.